Wai Chun Bio-Technology Sets 6 Nov 2026 Board Meeting to Approve FY 2026 Results; Share Trading Still Suspended
Bulletin Express
Oct 28
Wai Chun Bio-Technology Limited has scheduled a board meeting for 6 November 2026 at its Hong Kong headquarters. Directors will review and approve the audited annual results for the financial year ended 30 June 2026 and consider a potential final dividend.
Trading in the company’s shares has been halted since 9:00 a.m. on 2 October 2026 and will remain suspended until the FY 2026 results are released. Shareholders and prospective investors are urged to exercise caution when dealing in the company’s securities.
The current board comprises one executive director—Mr. Lam Ka Chun, who is also Chairman and Chief Executive Officer—and three independent non-executive directors: Mr. Wong Po Keung, Mr. Wang Ziniu and Ms. Xu Huiling.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.